Information  X 
Enter a valid email address

BTG PLC (BTG)

  Print      Mail a friend       Annual reports

Tuesday 13 July, 2010

BTG PLC

AGM Statement

RNS Number : 2912P
BTG PLC
13 July 2010
 



 

 

BTG plc: Results of 2010 Annual General Meeting

 

London, UK, 13 July 2010: BTG plc (LSE: BGC), the specialty pharmaceuticals company, announces that all resolutions were passed on a show of hands at its Annual General Meeting earlier today. The number of proxy votes lodged for each resolution prior to the meeting was as follows:

 


Total for*

Total against

Votes

withheld

Resolution

No. of

votes

% of

vote

No. of

votes

% of

vote

No. of

votes

1.

Receive accounts together with reports of the Directors and Auditor

186,528,596

99.86

256,219

0.14

1,021,402

2.

Approve the remuneration report

175,274,127

98.32

2,998,417

1.68

9,533,672

3.

Re-elect Louise Makin

186,517,625

99.88

230,527

0.12

1,058,065

4.

Re-elect Peter Chambré

186,536,429

99.88

225,023

0.12

1,044,765

5.

Re-appoint Auditor

184,864,584

98.98

1,910,898

1.02

1,030,734

6.

Fix Auditor remuneration

185,489,942

99.31

1,297,069

0.69

1,019,206

7.

Political donations

186,181,448

99.68

591,535

0.32

1,033,234

8.

Authority to allot shares

186,341,319

99.85

271,231

0.15

1,193,667

9.

Disapplication of pre-emption rights

186,688,337

99.96

69,420

0.04

1,048,460

10.

Adopt new articles of association

186,578,415

99.90

183,874

0.10

1,043,928

11.

Call a general meeting on not less than 14 days' notice

184,149,203

98.59

2,641,443

1.41

1,015,571

*Includes discretionary votes appointing the Chairman

 

For further information contact:

 

BTG

Financial Dynamics

Andy Burrows, Director of Investor Relations

+44 (0)20 7575 1741; mobile: +44 (0)7990 530605

Rolf Soderstrom, Chief Financial Officer

+44 (0)20 7575 0000  

Ben Atwell

+44 (0)20 7831 3113

 

About BTG

BTG is an international specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. The company is also seeking to acquire new products to develop and market to hospital specialists, and is building a sustainable business financed by revenues from sales of its critical care products and from royalties and milestone payments on partnered products. For further information, visit: www.btgplc.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGRJMATMBBBBTM